Monday, June 24, 2013

Isis Pharmaceuticals (ISIS) - news


  • 6/24/13: ISIS (26.47 +20.37%): Reported Phase 2 data on ISIS-APOCIII Rx showing significant reductions in triglycerides and APOC-III in patients with high triglycerides and type 2 diabetes
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)